What is HC Wainwright's Forecast for ACAD FY2027 Earnings?

Key Points

• HC Wainwright lowered ACADIA’s FY2027 EPS forecast to $1.87 from $1.89, while maintaining a Buy rating and $33 price target. The firm estimates EPS of $2.93 in FY2028, $3.26 in FY2029 and $3.40 in FY2030.
• ACADIA’s analyst consensus remains Moderate Buy, with 14 Buy ratings and four Holds and an average price target of $32.76.
• The company’s latest quarterly results exceeded expectations, with EPS of $0.18 versus the $0.07 consensus and revenue of $308 million, up 16.4% year over year.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at HC Wainwright cut their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Friday, September 25th. HC Wainwright analyst A. Ghosh now expects that the biopharmaceutical company will post earnings of $1.87 per share for the year, down from their prior forecast of $1.89. HC Wainwright currently has a "Buy" rating and a $33.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.64 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.93 EPS, FY2029 earnings at $3.26 EPS and FY2030 earnings at $3.40 EPS.

A number of other analysts have also weighed in on the stock. Morgan Stanley raised their price target on shares of ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the company an "equal weight" rating in a report on Tuesday, August 25th. Citizens Jmp reduced their price objective on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a "market outperform" rating on the stock in a report on Friday. UBS Group increased their price objective on ACADIA Pharmaceuticals from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Monday, August 17th. Citigroup reissued a "buy" rating and issued a $33.00 target price (down from $40.00) on shares of ACADIA Pharmaceuticals in a research note on Friday. Finally, Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, September 23rd. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.76.

ACADIA Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ ACAD opened at $20.53 on Tuesday. ACADIA Pharmaceuticals has a 1-year low of $19.69 and a 1-year high of $30.96. The company has a 50-day moving average of $27.41 and a two-hundred day moving average of $24.18. The company has a market cap of $3.54 billion, a PE ratio of 9.25 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The firm had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The company's revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 EPS.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 14,292 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the transaction, the executive vice president directly owned 67,828 shares of the company's stock, valued at approximately $1,981,934.16. This trade represents a 17.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total transaction of $432,660.54. Following the sale, the executive vice president directly owned 18,994 shares of the company's stock, valued at $496,313.22. This represents a 46.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 36,699 shares of company stock valued at $1,019,894. 26.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Nykredit A S acquired a new stake in shares of ACADIA Pharmaceuticals during the second quarter worth $38,000. Integrated Wealth Concepts LLC acquired a new position in ACADIA Pharmaceuticals in the second quarter valued at about $50,000. Global Retirement Partners LLC acquired a new position in ACADIA Pharmaceuticals in the second quarter valued at about $64,000. GAMMA Investing LLC boosted its holdings in ACADIA Pharmaceuticals by 15.6% during the second quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 402 shares during the last quarter. Finally, Transamerica Financial Advisors LLC bought a new position in ACADIA Pharmaceuticals during the second quarter worth about $104,000. Institutional investors and hedge funds own 96.71% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for neurological and psychiatric disorders. The company is headquartered in San Diego, California, and conducts research and commercial activities primarily in the United States.

ACADIA's marketed products include NUPLAZID (pimavanserin), an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome, a rare neurodevelopmental disorder.

Founded in 1993, ACADIA continues to advance a pipeline of therapies for central nervous system conditions, including additional neurological and psychiatric disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.